Oleksandra Los
Neurology · Oklahoma City, OKNPI 1871158964
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (56.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 86.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $11,850 and has fallen 85.1% since, to $1,762 in 2025.
Across 117 payments — averaging $152.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Boston Scientific$775
- Acadia Pharmaceuticals Inc$476
- AbbVie$306
- Amneal Pharmaceuticals LLC$138
- Biogen$122
- plus $604 from 16 others
What the payments were for
- Grants$10,00056%
- Travel & lodging$4,42325%
- Food & beverage$3,44219%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 62 | $15,447 |
| Boston Scientific | 5 | $775 |
| Acadia Pharmaceuticals Inc | 13 | $476 |
| AbbVie | 11 | $306 |
| Amneal Pharmaceuticals LLC | 2 | $138 |
| Biogen | 1 | $122 |
| Abbott | 1 | $116 |
| UCB, Inc. | 3 | $60 |
| Ipsen Biopharmaceuticals, Inc | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Genentech USA, Inc. | 2 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Lilly USA, LLC | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Novartis | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| CSL Behring | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA PC$10,122
- PERCEPT PC BRAINSENSE$3,426
- VERCISE$685
- NUPLAZID$124
- INFINITY$116
How this compares
$17,868 in reported general payments places this provider in the 75th percentile of 152 neurology providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $186,833 |
| RytaryCarbidopa/Levodopa | 62 | $74,601 |
| GocovriAmantadine Hcl | 19 | $47,800 |
| Rivastigmine | 22 | $4,051 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 50 | $3,284 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 102 | $2,940 |
| Rasagiline Mesylate | 20 | $2,295 |
| AmantadineAmantadine Hcl | 20 | $2,035 |
| RivastigmineRivastigmine Tartrate | 23 | $1,084 |
| Gabapentin | 27 | $615 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 16 | $545 |
| Midodrine Hcl | 12 | $315 |
| Lactulose | 16 | $303 |
| Escitalopram Oxalate | 19 | $261 |
| Buspirone Hcl | 16 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $47 | $186,83317 claims |
| Amneal Pharmaceuticals LLCRytary | $138 | $74,60162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 neurology providers in Oklahoma.
Other neurology in Oklahoma City
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Mariana VargaOklahoma City$183K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$158K
- Christi PendergraftOklahoma City$73K
- Courtney IserOklahoma City$56K
- Jeanne KingOklahoma City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.